色素上皮衍生因子治疗年龄相关性黄斑变性的研究进展  

Progress on study of treatment of age-related macular degeneration by pigment epithelial-derived factor

作　　者：侯慧媛[1] 王雨生[1] 

机构地区：[1]第四军医大学西京医院眼科全军眼科研究所,西安710032

出　　处：《中华眼科杂志》2010年第2期181-185,共5页Chinese Journal of Ophthalmology

摘　　要：年龄相关性黄斑变性（AMD）是世界范围内老年人致盲的主要疾病之一，探索治疗AMD的有效方法具有防盲治盲的重要意义。色素上皮衍生因子（PEDF）是最强效的内源性新生血管抑制剂，大量基础研究及Ⅰ期临床试验的结果表明，PEDF可有效治疗以脉络膜新生血管形成为主要特征的湿性AMD，因此，PEDF已成为目前最具潜能的治疗AMD的首选药物之一。Age-related macular degeneration （AMD） is a common cause of blindness in elderly population. Exploration of effective treatment of AMD has important significance. Pigment epithelial-derived factor （PEDF） is the most powerful endogenous inhibitor of angiogenesis. Increasing evidences, including results of phase Ⅰ clinical trial, indicated that PED17 could significantly inhibit the development of choroidal neovascularization, which is the characteristic of wet AMD. Therefore, PEDF is one of the most potential therapeutic agents for AMD treatment

关 键 词：黄斑变性 脉络膜新生血管化 眼蛋白质类 神经生长因子类 舍平类 

分 类 号：R774.1[医药卫生—眼科]